Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
Stopped early · Phase 1
Conditions studied: Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
In brief
A phase 1, first-in-human trial to evaluate the safety and tolerability of LAVA-051 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), or Acute Myeloid Leukemia (AML).
Key facts
- Study ID
- NCT04887259
- Run by
- Lava Therapeutics
- People needed
- 16
- Starts
- 2021-07-12
- Expected to finish
- 2023-09-06
- Last updated by the study team
- 2025-01-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Emory Winship Cancer Institute — Atlanta, Georgia, United States
- NYU Langone Health — New York, New York, United States
- Levine Cancer Institute, Atrium Health — Charlotte, North Carolina, United States
- Cleveland Clinic — Cleveland, Ohio, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- CHU Lille — Lille, France
- University Hospital of Nantes — Nantes, France
- Amsterdam UMC, location VUmc — Amsterdam, North Holland, Netherlands
- Amsterdam UMC, location AMC — Amsterdam, North Holland, Netherlands
- Erasmus MC — Rotterdam, South Holland, Netherlands
- University Hospital Vall d'Hebron — Barcelona, Spain
- Cima University of Navarra — Madrid, Spain
- Clinica Universida de Navarra — Pamplona, Spain
- Hospital Clinico Universitario de Salamanca — Salamanca, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.